Table of Contents
ISRN Anesthesiology
Volume 2011 (2011), Article ID 143189, 3 pages
http://dx.doi.org/10.5402/2011/143189
Clinical Study

No Perioperative Pulmonary Complications after Restricted Oxygen Exposition in Bleomycin-Treated Patients: A Short Report

1University Department of Anaesthesiology and Pain Therapy, University Hospital Bern, Inselspital, 3010 Berne, Switzerland
2Department of Urology, University Hospital Bern, 3010 Berne, Switzerland

Received 13 September 2011; Accepted 16 October 2011

Academic Editors: E. Freye and S. J. Verbrugge

Copyright © 2011 Patrick Y. Wuethrich and Fiona C. Burkhard. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Sleijfer, “Bleomycin-induced pneumonitis,” Chest, vol. 120, no. 2, pp. 617–624, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Hay, S. Shahzeidi, and G. Laurent, “Mechanisms of bleomycin-induced lung damage,” Archives of Toxicology, vol. 65, no. 2, pp. 81–94, 1991. View at Google Scholar · View at Scopus
  3. D. B. Chandler, “Possible mechanisms of bleomycin-induced fibrosis,” Clinics in Chest Medicine, vol. 11, no. 1, pp. 21–30, 1990. View at Google Scholar · View at Scopus
  4. J. A. Elias, B. Freundlich, J. A. Kern, and J. Rosenbloom, “Cytokine networks in the regulation of inflammation and fibrosis in the lung,” Chest, vol. 97, no. 6, pp. 1439–1445, 1990. View at Google Scholar · View at Scopus
  5. R. E. Smith, R. M. Strieter, S. H. Phan, N. Lukacs, and S. L. Kunkel, “TNF and IL-6 mediate MIP-1α expression in bleomycin-induced lung injury,” Journal of Leukocyte Biology, vol. 64, no. 4, pp. 528–536, 1998. View at Google Scholar · View at Scopus
  6. J. A. Levi, D. Raghavan, V. Harvey et al., “The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma,” Journal of Clinical Oncology, vol. 11, no. 7, pp. 1300–1305, 1993. View at Google Scholar
  7. D. S. Klein and P. R. Wilds, “Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications,” Canadian Anaesthetists Society Journal, vol. 30, no. 4, pp. 399–405, 1983. View at Google Scholar · View at Scopus
  8. D. D. Mathes, “Bleomycin and hyperoxia exposure in the operating room,” Anesthesia and Analgesia, vol. 81, no. 3, pp. 624–629, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Greif, O. Akça, E. P. Horn, A. Kurz, and D. I. Sessler, “Supplemental perioperative oxygen to reduce the incidence of surgical- wound infection,” New England Journal of Medicine, vol. 342, no. 3, pp. 161–167, 2000. View at Publisher · View at Google Scholar · View at PubMed
  10. B. Kabon and A. Kurz, “Optimal perioperative oxygen administration,” Current Opinion in Anaesthesiology, vol. 19, no. 1, pp. 11–18, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. J. Cersosimo, S. J. Matthews, and Waun Ki Hong, “Bleomycin pneumonitis potentiated by oxygen administration,” Drug Intelligence and Clinical Pharmacy, vol. 19, no. 12, pp. 921–923, 1985. View at Google Scholar · View at Scopus
  12. P. R. Grahmann, M. Brauer, L. Hüter, H. Sayer, R. Neumann, and R. K. Braun, “Respiratory failure and pulmonary fibrosis as a late side-effect after chemotherapy-induced by oxygen administration,” Pneumologie, vol. 59, no. 11, pp. 763–769, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. G. Kessell, S. Panchatsharam, E. Kothmann et al., “General anaesthesia for intralesional bleomycin therapy of vascular malformations: initial 3 yr experience,” British Journal of Anaesthesia, vol. 102, no. 3, pp. 431–432, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. M. Luis, A. Ayuso, G. Martinez, M. Souto, and J. Ortells, “Intraoperative respiratory failure in a patient after treatment with bleomycin: previous and current intraoperative exposure to 50% oxygen,” European Journal of Anaesthesiology, vol. 16, no. 1, pp. 66–68, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Uzel, M. Ozguroglu, B. Uzel et al., “Delayed onset bleomycin-induced pneumonitis,” Urology, vol. 66, no. 1, p. 195, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. M. Donat and D. A. Levy, “Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?” Journal of Urology, vol. 160, no. 4, pp. 1347–1352, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. O'Sullivan, R. A. Huddart, A. R. Norman, J. Nicholls, D. P. Dearnaley, and A. Horwich, “Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours,” Annals of Oncology, vol. 14, no. 1, pp. 91–96, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. P. L. Goldiner and O. Schweizer, “The hazards of anesthesia and surgery of bleomycin-treated patients,” Seminars in Oncology, vol. 6, no. 1, pp. 121–124, 1979. View at Google Scholar · View at Scopus
  19. S. C. Allen, G. S. Riddell, and E. G. Butchart, “Bleomycin therapy and anaesthesia. The possible hazards of oxygen administration to patients after treatment with bleomycin,” Anaesthesia, vol. 36, no. 1, pp. 60–63, 1981. View at Google Scholar · View at Scopus
  20. D. M. Libby, A. Gibofsky, and M. Fotino, “Immunogenetic and clinical findings in idiopathic pulmonary fibrosis. Association with the B-cell alloantigen HLA-DR2,” American Review of Respiratory Disease, vol. 127, no. 5, pp. 618–622, 1983. View at Google Scholar
  21. J. C. Hulbert, J. E. Grossman, and K. B. Cummings, “Risk factors of anesthesia and surgery in bleomycin-treated patients,” Journal of Urology, vol. 130, no. 1, pp. 163–164, 1983. View at Google Scholar · View at Scopus
  22. R. Catane, J. G. Schwade, and A. T. Turrisi III, “Pulmonary toxicity after radiation and bleomycin: a review,” International Journal of Radiation Oncology Biology Physics, vol. 5, no. 9, pp. 1513–1518, 1979. View at Google Scholar
  23. A. Serrano-Mollar, D. Closa, N. Prats et al., “In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats,” British Journal of Pharmacology, vol. 138, no. 6, pp. 1037–1048, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. E. Calzia, P. Asfar, B. Hauser et al., “Hyperoxia may be beneficial,” Critical Care Medicine, vol. 38, no. 10, supplement, pp. S559–S568, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus